嵌合HLA抗体受体T细胞特异性清除HLA-DQ特异性B细胞
研究开发了靶向HLA-DQ2和HLA-DQ7的嵌合HLA抗体受体(CHAR)T细胞,为首个HLA II类CHAR T细胞。体外、小鼠体内及致敏个体原代材料中,CHAR T细胞均能选择性清除相应HLA-DQ特异性B细胞,且免疫抑制剂影响有限。该疗法有望通过靶向脱敏扩大供体来源并治疗抗体介导的排斥反应。
要点
- HLA-DQ2/DQ7 CHAR T细胞可剂量依赖性清除对应HLA-DQ特异性B细胞。
- 体内及致敏个体原代材料中CHAR T细胞有效清除靶B细胞。
- 该抗原特异性疗法有望用于脱敏和抗体介导排斥反应治疗。
核心结论
- HLA-DQ2和HLA-DQ7 CHAR T细胞是首个HLA II类CHAR T细胞,能在体外、体内及致敏个体原代材料中选择性有效清除相应HLA-DQ特异性B细胞。
研究设计与样本
- 研究设计病毒载体编码HLA-DQ2或HLA-DQ7 CHAR分子,并在体外模型、免疫缺陷小鼠模型及致敏个体原代材料中评估CHAR T细胞功能。
主要发现
- 表达HLA-DQ2和HLA-DQ7 CHAR的原代CD8+ T细胞分别特异性清除HLA-DQ2或HLA-DQ7特异性B细胞,并产生干扰素γ、可溶性Fas配体、穿孔素和颗粒酶B。
- 与靶细胞共孵育时启动的维持免疫抑制方案对CHAR T细胞功能影响有限。
- HLA-DQ CHAR T细胞在体内小鼠模型及致敏个体原代材料中有效清除HLA-DQ特异性B细胞。
临床怎么用
- 该疗法可能通过靶向脱敏扩大供体可用性,并作为抗原特异性抗体介导排斥反应的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: HLA-DQ2/DQ7 chimeric HLA antibody receptor T cells, the first HLA class II chimeric HLA antibody receptor T cells, selectively eliminated cognate HLA-DQ-specific B cells in a dose-dependent manner. HLA-DQ chimeric HLA antibody receptor T cells efficiently depleted HLA-DQ-specific B cells with corresponding specificity in vivo . Chimeric HLA antibody receptor T-cell therapy expanded donor availability through targeted desensitization and represented a potential antigen-specific antibody-mediated rejection therapy. BACKGROUND: Chimeric antigen receptor T-cell therapy has revolutionized the treatment of hematologic malignancies by effectively eliminating tumor cells. In the field of kidney transplantation, comparable cellular therapies are being explored to facilitate transplantation and prevent graft rejection. Chimeric HLA antibody receptor (CHAR) T cells are a promising therapy for eliminating HLA-specific B cells in sensitized patients and potentially ameliorating antibody-mediated rejection. We previously demonstrated that HLA class I CHAR T cells selectively eliminated HLA class I-specific B cells with high specificity. Since HLA sensitization is most often directed against HLA-DQ of the allograft, we developed HLA-DQ2 and HLA-DQ7 CHAR T cells to target B cells with corresponding HLA specificity. METHODS: We designed viral vectors encoding HLA-DQ CHARs composed of HLA-DQA1*05:01 α chain with either HLA-DQB1*02:01 (HLA-DQ2) or HLA-DQB1*03:01 (HLA-DQ7) β chains, class II-associated invariant chain peptide, and intracellular 4-1BB costimulatory and CD3ζ signaling domains. Upon production of HLA-DQ CHAR T cells, we evaluated CHAR expression, cytotoxic activity, production of cytokines and cytotoxic mediators, and sensitivity to immunosuppressive drugs in in vitro models. We further assessed the cytotoxic activity of HLA-DQ CHAR T cells in an immunodeficient mouse model and in primary material from sensitized individuals. RESULTS: CHAR-transduced Jurkat triple parameter reporter cells expressing reporter constructs for T-cell activation markers showed robust activation upon specific stimulation. Primary CD8 + T cells expressing HLA-DQ2 and HLA-DQ7 CHAR molecules specifically eliminated HLA-DQ2- or HLA-DQ7-specific B cells, respectively, and produced interferon gamma, soluble Fas ligand, perforin, and granzyme B. Maintenance immunosuppressive drug regimens initiated at the time of coincubation with target cells had limited effects on CHAR T-cell functionality. Finally, HLA-DQ CHAR T cells effectively eliminated HLA-DQ-specific B cells in an in vivo mouse model, as well as in primary material from sensitized individuals. CONCLUSIONS: HLA-DQ2 and HLA-DQ7 CHAR T cells, the first HLA class II CHAR T cells, selectively and effectively eliminated corresponding HLA-DQ-specific B cells in vitro , in vivo , and in primary material from sensitized individuals.
引用
- Arana C, Gille I, Hagedoorn R, et al. Chimeric HLA Antibody Receptor T Cells to Specifically Eliminate HLA-DQ-Specific B Cells. J Am Soc Nephrol. 2026. PMID: 42690918. doi:10.1681/ASN.0000001244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。